| Literature DB >> 35854693 |
Lijun Wang1,1, Baihua Zhou1,2, Xinying Li1, Yang Wang3, Xiu Mei Yang1, Hongwei Wang1, Jun Yan1, Jiakun Dong1.
Abstract
Recent research has confirmed that moderate-intensity exercise affects the gut microbiome composition and improves cardiac function in an animal model after myocardial infarction (MI). However, few studies have investigated the effects of exercise on glucose and lipid metabolism in patients with coronary heart disease (CHD) receiving a statin treatment and successful percutaneous coronary intervention (PCI). Meanwhile, since statin therapy may lead to the risk of an increase in blood glucose level in CHD patients, we hypothesized that moderate-intensity exercise may be helpful for regulating glucose-lipid metabolism and stabilizing the blood glucose level in CHD patients. Therefore, to confirm our conjecture, we conducted a clinical retrospective study and animal experiment, respectively. The clinical study involved a total of 501 statin-treated patients with CHD after PCI. According to the study protocol, patients were divided into the following three groups: a non-exercise group, exercise at the recommended standard group, and exercise not at the recommended standard group. We found that qualified moderate-intensity exercise decreased blood glucose and lipid levels at follow-up at a mean of 2.2 years, and the incidence of new-onset diabetes showed a downward trend compared with the non-exercise and exercise not at the recommended standard groups. Furthermore, we used a high-fat rat model to explore an additional mechanism of the beneficial effects of exercise-based management on glucose-lipid metabolism apart from the known mechanism. We used 16S rRNA high-throughput sequencing technology to analyze the changes induced by exercise in the composition of intestinal flora in experimental rats. We found that rats that exercised with or without statin administration had lower plasma glucose and lipid levels and that these parameters were higher in the control and statin-treated rats that did not exercise. These results were consistent with the human study. The results from high-throughput sequencing of the intestinal flora of rats showed, to the best of our knowledge, that exercise leads to an increased relative abundance of Akkermansia muciniphila, which contributes to improved glucose and lipid metabolism. Based on our current results, we suggest that moderate-intensity exercise can improve glucose and lipid metabolism and prevent statin treatment-related side effects, such as hyperglycemia, in patients after PCI. Exercise could facilitate the applicability of statins for lower lipid levels. Exercise training also provides additional benefits, such as alteration of the gut microbiota, which contributes to improved glucose and lipid metabolism. ©2022 BMFH Press.Entities:
Keywords: coronary heart disease; exercise; intestinal microbiota; metabolism; percutaneous coronary intervention; statin
Year: 2022 PMID: 35854693 PMCID: PMC9246419 DOI: 10.12938/bmfh.2021-024
Source DB: PubMed Journal: Biosci Microbiota Food Health ISSN: 2186-3342
Fig. 1.Flow charts of the study design and treatments. (A) Clinical study. (B) Animal study. NE: no exercise group; NS: did not reach the exercise standard group; RS: reached the exercise standard group.
Comparison of blood glucose, lipids, and creatine kinase before and after statin treatment in each group
| Parameters (mmol/L) | NE (n=94) | NS (n=286) | RS (n=121) | |||
|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | |
| FPG | 7.28 ± 2.35 | 7.31 ± 2.30 | 7.23 ± 2.38 | 7.28 ± 2.14 | 7.38 ± 2.00 | 7.00 ± 1.70* |
| HbA1c (%) | 7.12 ± 1.65 | 7.38 ± 1.44# | 7.22 ± 1.65 | 7.29 ± 2.14 | 7.27 ± 1.53 | 7.25 ± 1.28 |
| TG | 1.85 ± 0.76 | 1.59 ± 0.59# | 1.83 ± 0.89 | 1.58 ± 0.55# | 1.85 ± 0.82 | 1.51 ± 0.74# |
| TC | 5.23 ± 0.92 | 4.34 ± 0.74# | 5.16 ± 0.93 | 4.01 ± 0.73# | 5.15 ± 0.90 | 3.55 ± 0.67* |
| HDL-C | 1.15 ± 0.31 | 1.19 ± 0.26 | 1.13 ± 0.28 | 1.16 ± 0.24 | 1.13 ± 0.27 | 1.17 ± 0.23 |
| LDL-C | 3.01 ± 0.86 | 2.07 ± 0.54# | 3.00 ± 0.93 | 1.82 ± 0.53# | 3.02 ± 0.96 | 1.61 ± 0.46# |
| CK (U/L) | 84.52 ± 25.63 | 86.63 ± 27.32 | 83.44 ± 32.52 | 84.18 ± 35.09 | 72.56 ± 30.21 | 73.26 ± 32.79 |
NE: no exercise group; NS: did not reach the exercise standard group; RS: reached the exercise standard group; FPG: fasting plasma glucose; HbA1C: hemoglobin A1C; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; CK: creatine kinase.
Fig. 2.Exercise improves glucose and lipid metabolism in coronary heart disease (CHD) patients after percutaneous coronary intervention (PCI). The changes of corresponding metabolic parameters were compared between baseline and follow-up among the three groups. One-way ANOVA was performed followed by a t-test. The D-value denotes the deviation value (D-value = baseline value − value at the time of follow-up). (A) Lipid metabolism-related parameters including TC, TG, HDL-C, and LDL-C. (B) Glucose metabolism-related parameters including FPG and HbA1C. (C) Percentages of new-onset diabetes (NOD) among the three groups. NE: no exercise group; NS: did not reach the exercise standard group; RS: reached the exercise standard group; FPG: fasting plasma glucose; HbA1C: hemoglobin A1C; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol. *p<0.05; **p<0.01.
Comparison of the incidences of cardiovascular events in the 3 groups
| Cardiovascular events | NE (n=94) | NS (n=286) | RS (n=121) |
|---|---|---|---|
| Cardiovascular death | 4 (4.26) | 3 (1.05) | 0#* |
| Recurrence of myocardial infarction | 6 (6.38) | 5 (1.75) | 1 (0.83)#* |
| Recurrence of angina pectoris and PCI | 8 (8.51) | 20 (6.70) | 7 (5.79)# |
| The overall event | 18 (19.15) | 28 (9.79) | 8 (6.61)#* |
N (%) NE: no exercise group; NS: did not reach the exercise standard group; RS: reached the exercise standard group; PCI: percutaneous coronary intervention.
Statistical analyses were conducted using A One way ANOVA followed by a TURKEY or Dunnett’s 3 test. *p<0.05 vs. NE group; #p<0.05 vs. NS group.
Fig. 3.Exercise decreases the levels of serum glucose and lipids and prevents statin therapy-related hyperglycemia in rats fed a high-fat diet. (A to E) Levels of FPG, TC, TG, HDL-C, and LDL-C in rats of the four experimental groups (A, control group; B, statins group; C, exercise and statins group; D, exercise group; n=10 for each group). Statistical analyses were conducted using one-way ANOVA followed by a Tukey or Dunnett’s T3 test. The results are presented as the mean ± standard deviation (SD). (F, G) Levels of GLU and LDL-C in rats received the combination of exercise and statin administration (group C) for 5 weeks and then statin administration for 5 weeks without the exercise training program (CA). *p<0.05; **p<0.01. FPG: fasting plasma glucose; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; GLU: glucose.
Fig. 4.Exercise regulates abundances and composition of intestinal microbiota in rats administered a high-fat diet (A to C). Determinations were performed 5 weeks after treatment. An linear discriminant analysis Effect Size (LEfSe) analysis was used for the calculations, and we defined the linear discriminant analysis (LAD) threshold as 2.0. A p value lower than 0.05 was defined as indicating statistical significance. A: control group; B: statins group; C: exercise and statins group; D: exercise group.
Fig. 5.Statistical analysis of the intestinal flora in the exercising and non-exercising groups. Analyses were performed with the Kruskal–Wallis rank sum test. (A) At the genus level. (B) At the species level. (C) linear discriminant analysis Effect Size (LEfSe) analysis of the intestinal microbiota in exercising rats. AB denotes the non-exercising groups: group A (control group) and group B (statins group). CD denotes the exercising groups: group C (exercise and statins group) and group D (exercise group).